Welcome to our dedicated page for Becton, Dickinson and Co. news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton, Dickinson and Co. stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology firm committed to advancing healthcare through the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Established in 1897, BD's mission is to enhance medical discovery, diagnostics, and care delivery. The company's extensive product portfolio serves healthcare institutions, physicians, life science researchers, and others across the globe.
BD is noted for being the world’s largest manufacturer and distributor of medical surgical products such as needles, syringes, and sharps-disposal units. The company also excels in producing pre-filled devices, diagnostic instruments, and reagents. Furthermore, BD offers sophisticated flow cytometry and cell-imaging systems. BD Medical represents nearly half of the company's total business, while BD Life Sciences and BD Interventional contribute 27% and 24% of the 2023 revenue, respectively. Impressively, international revenue accounts for 43% of the company's business.
Recent achievements and projects underscore BD's commitment to innovation and sustainability. The company recently collaborated with health care institutions in Denmark to explore recycling used blood collection tubes, achieving significant environmental advancements without compromising safety or quality.
In a pivotal development, BD announced the global commercial release of new cell sorters, enabling researchers in fields such as cell biology, cancer research, and immunology to gain new insights. The BD FACSDiscover™ S8 Cell Sorters incorporate groundbreaking technologies like BD CellView™ Image Technology and BD SpectralFX™ Technology, significantly enhancing real-time imaging and spectral flow cytometry.
BD also reported robust financial performance for the second quarter of fiscal 2024, highlighting strong operating margins and cash flow. This success led to an optimistic outlook and an increased earnings guidance, demonstrating the company’s resilience and strategic execution.
Further solidifying its market position, BD is set to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion. This acquisition expands BD’s portfolio in smart connected care solutions, leveraging advanced AI algorithms for better patient outcomes and adding significant value to its operations.
With a presence in almost every country and a workforce of over 70,000 employees, BD remains dedicated to advancing the world of health. The company works closely with customers and partners globally to address complex health challenges, enhance clinical outcomes, and expand access to healthcare.
BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.83 per common share, payable on September 30, 2021, with a record date of September 9, 2021. This sets the annual dividend rate at $3.32 per share, reflecting the company's commitment to delivering value to its shareholders. BD continues to be a leader in the medical technology sector, providing innovative solutions to enhance healthcare delivery globally.
BD (Becton, Dickinson and Company) announced its acquisition of Tepha, Inc., a developer of proprietary resorbable polymer technology, aimed at enhancing BD's surgical mesh portfolio. This acquisition facilitates vertical integration of the supply chain for BD's Phasix™ Mesh products. Tepha's GalaFLEX® products will bolster BD's capabilities in soft tissue repair and regeneration. The deal, expected to have an immaterial impact on BD's fiscal 2021 financial results, underscores the company's commitment to innovation in medical technology and enhancement of surgical solutions.
On July 23, 2021, a federal jury in Dallas found C.R. Bard's IVC blood clot filter defective, adding to a total of over $7 million in awards against the company. This marks the fourth jury ruling against Bard regarding these filters, which are linked to serious medical complications. The Recovery IVC filter caused significant issues when it fractured post-implantation. Lawyers representing affected individuals expressed intentions to continue pursuing cases until Bard acknowledges its responsibility for the product's safety risks.
BD (Becton, Dickinson and Company) has announced its acquisition of Velano Vascular, aiming to enhance patient experience through its 'One-Stick Hospital Stay' vision. This innovative approach utilizes Velano's PIVO™ device, allowing blood collection via existing PIVC lines, potentially reducing the need for multiple needlesticks. The initiative aligns with BD's long history of improving blood collection and vascular access. This acquisition supports BD's growth strategy to address unmet needs in healthcare. Financial terms of the acquisition were not disclosed.
On July 12, 2021, BD announced the appointment of David F. Melcher as non-executive chair and Claire Pomeroy as a director for its upcoming Diabetes Care spinoff, expected in H1 2022. The spinoff, subject to customary approvals, aims to establish a standalone entity poised for growth in the diabetes sector. Melcher brings extensive leadership experience, while Pomeroy offers insights from health care delivery. The transition is critical for NewCo, positioned as a major force in diabetes care.
BD (Becton, Dickinson and Company) has launched a new eCommerce platform at bdbiosciences.com aimed at enhancing the online purchasing experience for flow cytometry users. The website offers over 170 pages of new content, improved search capabilities, and customized dashboards for streamlined purchases. Available in the U.S., Canada, Europe, Australia, and New Zealand, the platform integrates with procurement systems, ensuring institutional pricing and approval processes are simplified. BD aims to empower researchers and lab managers by addressing their purchasing needs effectively.
BD (Becton, Dickinson and Company) will announce its third quarter fiscal 2021 financial results on August 5, 2021, at approximately 6:00 a.m. ET. A conference call will follow at 8:00 a.m. ET for discussions on the results, operations, and strategy. The event will be available for replay until August 12, 2021. Additionally, BD plans to host an Investor Day on November 12, 2021, with more details to be shared later. For further information, visit bd.com/investors.
BD (Becton, Dickinson and Company) announced it received 510(k) clearance from the FDA for its PeritX™ Peritoneal Catheter System to drain symptomatic, recurrent non-malignant ascites. This system, which expands on the existing PleurX™ system, allows patients to manage their condition at home, reducing hospital visits. The PeritX™ is now the first FDA-approved tunneled catheter for both malignant and non-malignant ascites, improving patient care and comfort.
BD (Becton, Dickinson and Company) has partnered with USA Swimming to provide COVID-19 testing using the BD Veritor™ Plus System at various swimming events, including the U.S. Olympic Team Trials in June 2021. This initiative includes over 2,000 rapid antigen tests, supplementing existing PCR testing protocols to enhance athlete safety. BD's rapid testing technology delivers results in 15 minutes, promoting health and safety for competitors. This collaboration underscores BD's commitment to supporting athletes and ensuring safe participation in sports amidst the pandemic.
FAQ
What is the current stock price of Becton, Dickinson and Co. (BDX)?
What is the market cap of Becton, Dickinson and Co. (BDX)?
What does Becton, Dickinson and Company (BD) specialize in?
What are BD's main business segments?
What recent projects has BD undertaken?
How much of BD's revenue comes from international markets?
What significant acquisition has BD announced recently?
How many employees does BD have?
Where can I find more information about BD's financial performance?
What is the significance of the BD FACSDiscover™ S8 Cell Sorters?
Which regulatory body recently issued a safety communication regarding syringes?
What is BD's approach to sustainability?
